Physician profile
Luis E Alvarez
NPI 1174599559
$8,483.99
in general payments reported to CMS, 2019-2025
31 companies · $2,032 in 2025
The $2,032 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $843 · 2021: $1,047 · 2022: $954 · 2023: $1,179 · 2024: $1,666 · 2025: $2,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,630 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,629.61 |
| Education | $247.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,459.96 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $976.10 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $938.87 | 2019-2025 | Trulance, Relistor, Xifaxan |
| Qol Medical, LLC | $521.90 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $391.06 | 2020-2025 | Entyvio, Eohilia |
| Pfizer INC. | $309.15 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $296.41 | 2020-2025 | Ocaliva |
| Ardelyx, INC. | $244.41 | 2022-2025 | Ibsrela |
| Celltrion USA INC. | $175.74 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $147.15 | 2023-2025 | Voquezna |
| Gilead Sciences, INC. | $132.18 | 2019-2025 | |
| Madrigal Pharmaceuticals | $116.04 | 2025 | Rezdiffra |
| Shionogi INC | $103.96 | 2019 | |
| Redhill Biopharma INC. | $100.61 | 2020-2023 | Aemcolo, Movantik, Talicia |
| Genzyme Corporation | $77.11 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mauna Kea Technologies, INC. | $72.42 | 2019-2023 | |
| Braintree Laboratories, INC. | $55.26 | 2020-2024 | Sutab, Suflave |
| Lilly USA, LLC | $48.88 | 2023-2024 | Omvoh |
| Celgene Corporation | $48.41 | 2023-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $42.07 | 2022-2024 | Dificid |
| Exact Sciences Corporation | $41.19 | 2024-2025 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $33.35 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.10 | 2023 | Cyltezo |
| Ferring Pharmaceuticals INC. | $18.38 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.18 | 2024 | |
| Ethicon US, LLC | $16.95 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.15 | 2024 | |
| Mylan Institutional INC. | $15.46 | 2023 | |
| Novo Nordisk INC | $15.06 | 2025 | Wegovy |
| Napo Pharmaceuticals INC | $11.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.